Fintel reports that on October 14, 2025, D. Boral Capital maintained coverage of Medicus Pharma (NasdaqCM:MDCX) with a Buy recommendation. Analyst Price Forecast Suggests 746.41% Upside As of ...

The lectureship was established in 2000 by the UB Department of Pharmaceutical Sciences to honor Gerhard Levy, PharmD, UB distinguished professor emeritus of pharmaceutical sciences, for his ...

Danaher posted higher third-quarter earnings and said it expects pharmaceutical companies to increase research-and-development spending as tariff uncertainty eases. “We do see the tariff situation ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...

Affinity Education Group on Tuesday confirmed chief executive Tim Hickey and chief operating officer Nishad Alani had left the organisation. The company owns and operates more than 225 early education ...

Biopharma data showed M&A strength, selective venture capital favoring Phase II, record obesity deals, and significant upfronts flowing toward innovation in China were key in Q3 2025. The newly ...

STATEN ISLAND, N.Y. — Little by little, you could see an increase in confidence by St. Peter’s as its game vs. CHSFL AAA opponent Cardinal Hayes progressed. But, perhaps, there was no better example ...

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b ...

The Pacers can’t catch a break at point guard. Andrew Nembhard left Thursday’s opener against Oklahoma City with left shoulder soreness and didn’t return — another blow for a team already decimated in ...

More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. The FDA has signed off on a label update for ...

The Affinity Education Group confirmed on Tuesday that its chief executive Tim Hickey and its chief operating officer, Nishad Alani, had “stepped down from their roles and have left the organisation”.